PL1819230T3 - Makrocząstki pochodzące z czerwonych krwinek jako czynniki hemostatyczne do kontrolowania krwotoku i do leczenia zaburzeń krwawienia - Google Patents

Makrocząstki pochodzące z czerwonych krwinek jako czynniki hemostatyczne do kontrolowania krwotoku i do leczenia zaburzeń krwawienia

Info

Publication number
PL1819230T3
PL1819230T3 PL05849361T PL05849361T PL1819230T3 PL 1819230 T3 PL1819230 T3 PL 1819230T3 PL 05849361 T PL05849361 T PL 05849361T PL 05849361 T PL05849361 T PL 05849361T PL 1819230 T3 PL1819230 T3 PL 1819230T3
Authority
PL
Poland
Prior art keywords
microparticles
derived
hemorrhage
treatment
control
Prior art date
Application number
PL05849361T
Other languages
English (en)
Inventor
Wenche Jy
Joaquin J Jimenez
Lawrence L Horstmann
Yeon S Ahn
Eugene Ahn
Original Assignee
Univ Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Miami filed Critical Univ Miami
Publication of PL1819230T3 publication Critical patent/PL1819230T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL05849361T 2004-12-07 2005-12-07 Makrocząstki pochodzące z czerwonych krwinek jako czynniki hemostatyczne do kontrolowania krwotoku i do leczenia zaburzeń krwawienia PL1819230T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63341704P 2004-12-07 2004-12-07
EP05849361A EP1819230B1 (en) 2004-12-07 2005-12-07 Red cell-derived microparticles as hemostatic agents for the control of hemorrhage and for treatment of bleeding disorders
PCT/US2005/044064 WO2006062945A2 (en) 2004-12-07 2005-12-07 Cell-derived microparticles as hemostatic agents for control of hemorrhage and treatment of bleeding disorders

Publications (1)

Publication Number Publication Date
PL1819230T3 true PL1819230T3 (pl) 2013-02-28

Family

ID=36578476

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05849361T PL1819230T3 (pl) 2004-12-07 2005-12-07 Makrocząstki pochodzące z czerwonych krwinek jako czynniki hemostatyczne do kontrolowania krwotoku i do leczenia zaburzeń krwawienia

Country Status (9)

Country Link
US (1) US8105632B2 (pl)
EP (1) EP1819230B1 (pl)
JP (1) JP5204490B2 (pl)
AT (1) ATE555799T1 (pl)
DK (1) DK1819230T3 (pl)
ES (1) ES2390317T3 (pl)
PL (1) PL1819230T3 (pl)
PT (1) PT1819230E (pl)
WO (1) WO2006062945A2 (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9155764B1 (en) * 2004-12-07 2015-10-13 University Of Miami Expanded utility of red-cell derived microparticles (RMP) for treatment of bleeding
CN101304748A (zh) 2005-08-22 2008-11-12 加利福尼亚大学董事会 Tlr激动剂
BRPI0807196A2 (pt) * 2007-02-07 2014-06-03 Univ California Método para prevenir ou inibir uma infecção bacteriana, vacina, composto, e, método para prevenir, tratar ou inibir a asma
FR2917172B1 (fr) * 2007-06-07 2014-01-03 Inst Nat Sante Rech Med Methode de mesure de l'activite plasmine des microparticules presentes dans un echantillon de fluide biologique et utilisation
US20090062233A1 (en) 2007-08-09 2009-03-05 Xin Ji Modified starch material of biocompatible hemostasis
US20120116817A1 (en) * 2009-07-01 2012-05-10 Chantal Boulanger Methods for Predicting Cardiovascular Mortality Risk
WO2012048275A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
NO2668262T3 (pl) * 2011-01-28 2018-04-28
JP2012168012A (ja) * 2011-02-14 2012-09-06 Nippon Koden Corp 血管内皮障害を検査するための新規な検査方法および検査用キット
WO2012135032A2 (en) * 2011-03-25 2012-10-04 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
US10004764B2 (en) 2013-11-07 2018-06-26 University of Pittsburgh—of the Commonwealth System of Higher Education Red blood cell membrane-derived microparticles and their use for the treatment of lung disease
WO2015073913A1 (en) 2013-11-16 2015-05-21 Terumo Bct, Inc. Expanding cells in a bioreactor
US11008547B2 (en) 2014-03-25 2021-05-18 Terumo Bct, Inc. Passive replacement of media
US10538738B2 (en) * 2014-05-19 2020-01-21 Eleftherios Papoutsakis Megakaryocytic particles and microparticles for cell therapy and fate modification of stem and progenitor cells
WO2016049421A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled feed
WO2016141325A1 (en) 2015-03-04 2016-09-09 University Of Rochester Systemic and topical application of platelet microparticles to treat bleeding in trauma patients
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
WO2017062422A1 (en) * 2015-10-07 2017-04-13 The Research Foundation For The State University Of New York METHODS FOR INCREASING PLATELET COUNT BY INHIBITING BILIVERDIN IXβ REDUCTASE
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
EP3464565A4 (en) 2016-05-25 2020-01-01 Terumo BCT, Inc. CELL EXPANSION
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
JP6896516B2 (ja) * 2016-07-25 2021-06-30 シスメックス株式会社 血液分析装置および血液分析方法
CN110799199B (zh) 2016-11-30 2024-01-30 迈阿密大学 Rmp组合物及使用方法
EP3656842A1 (en) 2017-03-31 2020-05-27 Terumo BCT, Inc. Cell expansion
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
JP2024511064A (ja) 2021-03-23 2024-03-12 テルモ ビーシーティー、インコーポレーテッド 細胞捕獲及び増殖
CN117752686A (zh) * 2022-11-18 2024-03-26 中山大学 囊泡在制备体外促凝血或体外止血药物中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1131106B1 (en) * 1998-11-12 2009-06-24 Novolytics Inc. Compositions and methods for producing vascular occlusion

Also Published As

Publication number Publication date
WO2006062945A2 (en) 2006-06-15
PT1819230E (pt) 2012-08-07
EP1819230A4 (en) 2009-08-12
JP2008522974A (ja) 2008-07-03
US8105632B2 (en) 2012-01-31
JP5204490B2 (ja) 2013-06-05
ATE555799T1 (de) 2012-05-15
WO2006062945A3 (en) 2006-12-07
US20080069807A1 (en) 2008-03-20
EP1819230A2 (en) 2007-08-22
EP1819230B1 (en) 2012-05-02
ES2390317T3 (es) 2012-11-08
DK1819230T3 (da) 2012-08-20

Similar Documents

Publication Publication Date Title
PL1819230T3 (pl) Makrocząstki pochodzące z czerwonych krwinek jako czynniki hemostatyczne do kontrolowania krwotoku i do leczenia zaburzeń krwawienia
EP4026835A3 (en) Pd-1/pd-l1 inhibitors
PH12020551062A1 (en) 1,2,4-oxadiazole compounds as inhibitors of cd47 signalling pathways
MX2021001186A (es) Purinonas como inhibidores de proteasa especifica de ubiquitina 1.
AU2018236800B2 (en) DNA-PK inhibitors
EA201891268A1 (ru) Соединения, которые можно применять в качестве ингибиторов киназы
MX2019002564A (es) Composiciones de agente de unión de albúmina-paclitaxel y métodos de uso y elaboración de las mismas.
EP4276114A3 (en) Cd20 binding single domain antibodies
PH12015501656B1 (en) Anti-il-33 antibodies and use thereof
PH12015502388A1 (en) Compositions and methods for altering second messenger signaling
NZ701121A (en) Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof
PH12020500343A1 (en) Pyruvate kinase activators for use in treating blood disorders
ATE553093T1 (de) Indazolderivate zur hemmung von trpv1 und verwendungen davon
MX2020002399A (es) Inhibidores del enlace proteína-proteína de wdr5.
EA201691235A1 (ru) Модифицированные серпины для лечения нарушений свертываемости крови
GEP201706741B (en) Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
TW200734306A (en) Novel compounds, their preparation and use
MX2012013078A (es) Composiciones antimicrobianas liquidas de baja formacion de espuma, modificadas reologicamente, y sus metodos de uso.
MX2020002435A (es) Agentes que modulan las funciones de beta-catenina y sus métodos.
EA201501123A8 (ru) Новые (циано-диметил-метил)-изоксазолы и -[1,3,4]тиадиазолы
WO2017007886A3 (en) Compositions for inhibiting dux4 gene expression and uses thereof
MX2022014220A (es) Inhibidores de calmodulin, inhibidores de chk2 e inhibidores de rsk para el tratamiento de trastornos ribosomales y ribosomatopias.
IL184292A0 (en) Treatment of drug-resistant proliferative disorders
MX2022007207A (es) Composiciones y metodos para tratar y prevenir la influenza.
MX2020006533A (es) Inhibidores del receptor activado por proteasa-2.